Posted by Michael Wonder on 01 Mar 2019
Patient access to cost-effective treatments increased with launch of new biosimilar in Canada
28 February 2019 - First-ever pegfilgrastim biosimilar approved by Health Canada launches across the country.
Apobiologix, a division of Apotex Inc., yesterday launched the first biosimilar pegfilgrastim approved by Health Canada. The company, focused on the development of biosimilars for global markets, launched Lapelga nationally.
Health Canada's approval of Lapelga was, in fact, the first-ever pegfilgrastim biosimilar approved in any highly regulated market worldwide. Now with the launch of Lapelga, Apobiologix is the only company to offer a portfolio of cranulocyte colony-stimulating factor biosimilars in Canada. This portfolio offers a potential savings of more than $42 million per year.
